If the stock price continues to rise in the future, an application for suspension and investigation may be submitted to the Shenzhen Stock Exchange. 7 consecutive limit-up big bull stock urgently issues an abnormality announcement | Post-market announcement roundup

Today’s Focus

【7 consecutive limit-ups for Yunnan Energy Holdings: If the stock price continues to rise in the future, the company may apply for a trading suspension and investigation with the Shenzhen Stock Exchange】

Yunnan Energy Holdings (001896.SZ) announced that from February 25 to 27, 2026, the closing prices of the company’s stock deviated by more than 20% for three consecutive trading days. Since February 9, the closing price deviation has reached a total of 100.61% over nine consecutive trading days. This constitutes a serious abnormal fluctuation in stock trading. If the stock price continues to rise, the company may apply for a trading suspension and investigation with the Shenzhen Stock Exchange. Investors participating in trading may face significant risks. The company solemnly reminds investors: the company’s investment in Xiantian Computing Power, established on March 27, 2024, had total assets of 19.62 million yuan, net assets of 4.22 million yuan, operating income of 22.17 million yuan, and net profit of 190,000 yuan by the end of 2025. The financing work with potential acquirers for Xiantian Computing Power is still ongoing. The acquisition also requires antitrust review for concentrated market operation. The overall transaction is very complex and uncertain, with a risk of non-completion. The company also reminds investors: the data center (IDC) industry to which the target company belongs currently faces fierce market competition and increasing internal cost controls among clients, which may lead to a decline in overall gross profit margin of the IDC industry. If effective measures are not taken to respond to major market and policy changes in the data center industry, and if core competitiveness cannot be continuously improved, it may adversely affect the target company’s operations. Please make rational decisions, invest cautiously, and be aware of secondary market trading risks.

【7 days 5 limit-ups for Zhangyuan Tungsten: Tungsten products are widely used in aerospace and other fields; macroeconomic environment will influence market demand and tungsten prices, thereby affecting company performance】

Zhangyuan Tungsten (002378.SZ) announced that on February 26 and 27, 2026, the stock price increased by a total deviation of 20.38%, indicating abnormal trading fluctuations. The company faces the following risks in its operations: First, market risk. Tungsten products are widely used in machining, aerospace, defense, electronics, and transportation sectors. The macroeconomic environment will impact market demand and tungsten prices, affecting company performance. Second, raw material price fluctuation risk. The national control and quota management of tungsten mining may cause prices to spike and then fall, and cost pressures in the supply chain may hinder transmission. Third, exchange rate fluctuation risk. The company’s and its wholly owned subsidiary Ganzhou Aoketai Tool Technology Co., Ltd.'s export revenues are mainly settled in USD. Significant fluctuations in USD to RMB exchange rates may impact performance. Fourth, credit risk. The company grants credit limits and payment terms to some customers based on historical cooperation and creditworthiness, but there is a risk of bad debts. There is also a risk of default if customers fail to take delivery as agreed or suppliers fail to deliver products as scheduled, which could affect operations.

【5 days 3 limit-ups for TaiJia Co.: Data center power supply business accounted for a small proportion in 2025 and does not involve AI chip business】

TaiJia Co. (002843.SZ) announced that the stock price increased by more than 20% deviation over two consecutive trading days, indicating abnormal trading fluctuations. The company’s sawing products are not used in photovoltaic silicon wafer cutting. The main sawing products are bimetal band saw blades, used for cutting black metals, non-ferrous metals, graphite, foam materials, and wood, but not for photovoltaic silicon wafer cutting. Investors are advised to exercise caution and be aware of investment risks. In 2025, the company’s data center power supply business revenue was approximately 30.69 million yuan, accounting for about 2.01%, a small proportion, and it does not involve AI chip business. The company’s data center power supply segment mainly provides OEM services for server power modules. This business generated about 30.69 million yuan in 2025, representing about 2.01% of total revenue. These figures are unaudited. Investors should be cautious and aware of risks.

【3 days 2 limit-ups for Zhongwutai High-tech: Main risks include continued rise and potential fall of tungsten prices and supply chain cost transmission issues】

Zhongwutai High-tech (000657.SZ) announced that the stock price deviated by more than 20% over three consecutive trading days, indicating abnormal trading fluctuations. The main risks faced include: First, industry and macro risks. Performance is strongly correlated with macroeconomic conditions; fluctuations may impact overall manufacturing demand. Second, raw material price fluctuation risk. Continued rise in tungsten prices may lead to a sharp correction and supply chain cost transmission issues. Third, operational and business development risks. The company needs to monitor the recovery of hard alloy consumption and the slowdown in demand growth in industries like PCB.

Share Reduction & Increase

【Hua An Securities: Controlling shareholder Anhui Guokong Group plans to purchase convertible bonds and convert to increase holdings】

Hua An Securities (600909.SH) announced that its controlling shareholder, Anhui Guokong Group, plans to purchase convertible bonds and convert to increase its holdings of the company’s shares from March 2 to March 6, 2026, with a total investment of 150 million to 300 million yuan, not exceeding a 2% increase. The funds will come from its own resources, and it commits not to sell within six months after the increase.

【Aidi Pharmaceuticals: One of the actual controllers, Chairman Fu Heliang, plans to increase holdings by 10-15 million yuan】

Aidi Pharmaceuticals (688488.SH) announced that one of its actual controllers and chairman, Fu Heliang, plans to increase holdings of A-shares within six months starting March 2, 2026, via centralized bidding or block trades, with a minimum of 10 million yuan and up to 15 million yuan, funded by self-raised or self-owned funds.

Operations & Performance

【SAIC Motor: Vehicle sales of 596,900 units in the first two months, up 6.76% year-on-year】

SAIC Motor (600104.SH) announced that in February 2026, vehicle sales were 269,500 units, down 8.64% year-on-year. From January to February, total vehicle sales reached 596,900 units, up 6.76% compared to the same period last year. Among these, new energy vehicle sales for January-February totaled 156,700 units, up 6.44%; exports and overseas sales for the same period totaled 203,600 units, up 48.92%.

【BAIC BluePark: February new energy vehicle production of 7,631 units, up 16.43% year-on-year】

BAIC BluePark (600733.SH) announced that Beijing New Energy Vehicle Co., Ltd. produced 7,631 units in February 2026, a 16.43% increase year-on-year; sales were 7,364 units, up 18.26%. Cumulative production for January-February was 18,800 units, up 19.01%; cumulative sales were 15,437 units, up 14.81%.

【Great Wall Motors: February new energy vehicle sales of 12,744 units】

Great Wall Motors (601633.SH) announced that in February 2026, sales reached 72,594 units; for January-February, total sales were 162,906 units, up 2.58%. February new energy vehicle sales were 12,744 units, with 30,773 units sold in the first two months.

Awards & Bidding

【Henghua Technology: Preliminarily awarded a 630 million yuan wind power EPC project】

Henghua Technology (300365.SZ) announced that it participated in the bid for the “Longhua County 100MW Wind Power EPC Project” and was listed as the first candidate for award, with a bid price of 630 million yuan. The project plans to install 100MW of wind capacity, with a construction period of 296 calendar days. If awarded and successfully implemented, it is expected to positively impact the company’s future performance.

【Kanghong Pharmaceutical: Eight products selected in national centralized procurement, procurement cycle until end of 2028】

Kanghong Pharmaceutical (002773.SZ) announced that eight products, including Montelukast Sodium Tablets, Ropinirole Tablets, Venlafaxine Hydrochloride Extended-Release Tablets, Aripiprazole Orally Disintegrating Tablets, Escitalopram Oxalate Tablets, Pramipexole Hydrochloride Extended-Release Tablets, Quetiapine Fumarate Tablets, and Sodium Hyaluronate Eye Drops, have been included in the national centralized procurement continuation list. Among these, Quetiapine Fumarate Tablets and Sodium Hyaluronate Eye Drops are participating in the renewal for the first time. The implementation of the winning results is planned for March 2026, with the procurement cycle ending on December 31, 2028.

【YiduoLi: Subsidiary’s phytase product approved for EU registration】

YiduoLi (300381.SZ) announced that its wholly owned subsidiary, Victory Enzymes GmbH in Germany, received approval from the European Commission for its phytase product, which can be used as a feed additive for pigs, poultry, and some birds in the EU market, with approval valid until March 17, 2036. This approval enriches the company’s product portfolio in the EU, enhances global layout, and improves market competitiveness and brand influence. However, future sales are uncertain; investors should be cautious.

【Zhongyuan Xiehe: Subsidiary received medical device registration certificate, product is the first domestic flight time mass spectrometry-based tumor companion diagnostic kit】

Zhongyuan Xiehe (600645.SH) announced that its controlling subsidiary recently obtained a medical device registration certificate (Class III) for a gene mutation detection kit (using flight time mass spectrometry) for EGFR/KRAS/BRAF/ERBB2/PIK3CA mutations. This is the first domestically approved tumor companion diagnostic kit based on flight time mass spectrometry, used for detecting gene mutations in non-small cell lung cancer and colorectal cancer patients, with related drugs included in the national medical insurance catalog. The product’s approval enriches the company’s tumor companion diagnostics portfolio, but its future impact on performance is unpredictable.

【Lepu Medical: MWX401 injection approved for clinical trials for primary hypertension】

Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotechnology Co., Ltd., received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration (NMPA) for MWX401 injection. The drug, a Class 1 chemical medicine, is indicated for primary hypertension and is a proprietary siRNA drug developed by Minwei Biotech.

【Xinpai Medical: Breakthrough designation by US FDA for multi-branch thoracic stent, expected to accelerate international market entry】

Xinpai Medical (688016.SH) announced that its innovative Hector®/Tongtianji™ thoracic aortic multi-branch covered stent system received Breakthrough Device designation from the US FDA on February 27, 2026. The product is used for minimally invasive treatment of thoracic aortic lesions involving the arch’s three branches. This designation allows the FDA to expedite development and prioritize review, potentially accelerating entry into international markets including the US.

Others

【Huiyu Pharmaceutical: Revised 2025 performance forecast, recognizing fair value change gains of -1.73 billion yuan】

Huiyu Pharmaceutical (688553.SH) issued a correction to its 2025 performance forecast, confirming that during the reporting period, the fair value change gains from its investment in Zhejiang Tongyuan Kang Medical Co., Ltd., listed on the Hong Kong Stock Exchange, amounted to -1.73 billion yuan. Other contents of the original announcement remain unchanged. We apologize for any inconvenience caused to investors and thank you for your understanding.

【Chinese Online: Submitted application for H-share listing on Hong Kong Stock Exchange】

Chinese Online (300364.SZ) announced that on February 27, 2026, it submitted an application for the issuance and listing of overseas listed H-shares on the Hong Kong Stock Exchange and published the relevant application materials on the HKEX website.

【Shitou Shares: Suspended review of major asset restructuring due to expired financial data】

Shitou Shares (600539.SH) announced that the financial data used for the issuance of shares and cash purchase of assets and related fundraising, which was audited, expired on February 28, 2026. The Shanghai Stock Exchange has notified the suspension of review. The company will conduct an extended audit and update materials, and will reapply for review after completion. The suspension will not have a significant adverse impact on the transaction.

【Hua Xia Happiness: Temporarily appointed management to publicly recruit restructuring investors】

Hua Xia Happiness (600340.SH) announced that the Intermediate People’s Court of Langfang City, Hebei Province, has accepted the company’s pre-restructuring case and appointed Hua Xia Happiness Judicial Restructuring and Liquidation Team as the temporary management during pre-restructuring. The temporary management will conduct a public recruitment of potential restructuring investors to provide additional funds and resources, aiming to coordinate and complete the pre-restructuring and possible restructuring, safeguarding the legal rights and interests of creditors, shareholders, and other stakeholders.